Bio

Allen joined Chestnut Partners in 2023. Prior to joining Chestnut, he served as Chief Business Officer at Voyager Therapeutics, a publicly-traded biotechnology company focused on developing gene therapies for severe neurological disease. During his five-year tenure at Voyager, Mr. Nunnally led transactions that generated $500 million up front and the potential for over $10 billion including milestone payments. Prior to Voyager, Mr. Nunnally served as Vice President of Corporate and Business Development and Associate General Counsel at Foundation Medicine, a cancer genomic diagnostics company. At Foundation Medicine, he led transactions relating to its biopharmaceutical business and directed the company’s intellectual property strategy. Mr. Nunnally represented Foundation Medicine in its Series B financing and oversubscribed IPO and co-led the expansive R&D collaboration transaction at the core of Roche’s $1 billion+ purchase of a majority interest in, and subsequent complete acquisition of, the company. Mr. Nunnally previously spent 10 years at the law firm Wilmer, Cutler, Pickering, Hale and Dorr LLP, representing organizations ranging from Fortune 500 biopharma companies to early-stage biotech startups. He serves on the board of directors of Friends of the Children-Boston, a non-profit organization that supports underserved children with intensive, professional mentoring from kindergarten all the way through high-school graduation to help them achieve their greatest potential. Mr. Nunnally holds a B.A. from Amherst College, where he double majored in in biology and law, jurisprudence and social thought, and a J.D. from Boston University School of Law with a concentration in intellectual property law. Registrations: FINRA Series 79, 7, and 63.